首页> 美国卫生研究院文献>The Journal of Clinical and Aesthetic Dermatology >Evaluation of the Efficacy and Safety of a Lidocaine and Tetracaine (7/7) Cream for Induction of Local Dermal Anesthesia for Facial Soft Tissue Augmentation with Hyaluronic Acid
【2h】

Evaluation of the Efficacy and Safety of a Lidocaine and Tetracaine (7/7) Cream for Induction of Local Dermal Anesthesia for Facial Soft Tissue Augmentation with Hyaluronic Acid

机译:利多卡因和四卡因(7%/ 7%)乳膏诱导局部皮肤麻醉以透明质酸增强面部软组织的效果和安全性评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Injection of dermal fillers for soft tissue augmentation is a minimally invasive cosmetic procedure with growing popularity. However, patients often express concern about pain with such procedures. A topical anesthetic cream formulated with lidocaine/tetracaine 7%7% was approved by the United States Food and Drug Administration in 2006 and recently reintroduced to the market for use during superficial dermatological procedures. A Phase 3 study was conducted to assess the efficacy and safety of lidocaine/tetracaine 7%7% cream versus placebo cream when used to induce local dermal anesthesia during injections with hyaluronic acid. Mean visual analog scale scores significantly favored lidocaine/tetracaine 7%7% cream. A significant percent of subjects also indicated that lidocaine/tetracaine 7%7% cream provided adequate pain relief and that they would use lidocaine/tetracaine 7%7% cream again. Investigators also rated lidocaine/tetracaine 7%7% cream significantly better than placebo cream for providing adequate pain relief and on the assessment of pain scale. Lidocaine/tetracaine 7%7% cream was safe and well tolerated with most subjects reporting no erythema, edema, or blanching. No related adverse events were reported with lidocaine/tetracaine 7%7% cream; one related adverse event of erythema was reported with placebo cream. The results of this study indicate that lidocaine/tetracaine 7%7% cream is efficacious and safe at providing pain relief for soft tissue augmentation with hyaluronic acid.
机译:注射真皮填充剂用于软组织增强是一种微创美容程序,越来越受欢迎。但是,患者通常会对此类手术引起的疼痛表示担忧。由利多卡因/丁卡因7%7%配制的局部麻醉乳膏于2006年获得美国食品和药物管理局的批准,最近重新投放市场,以用于浅层皮肤病学手术。进行了一项3期研究,以评估在注射透明质酸期间用于诱导局部皮肤麻醉的利多卡因/丁卡因7%7%乳膏与安慰剂乳膏的疗效和安全性。平均视觉模拟量表评分显着偏重利多卡因/丁卡因7%7%乳膏。相当大比例的受试者还指出,利多卡因/丁卡因7%7%的乳膏可缓解疼痛,并且他们将再次使用利多卡因/丁卡因7%7%的乳膏。研究人员还对利多卡因/丁卡因7%7%的乳膏评级比安慰剂乳膏明显好,以提供足够的疼痛缓解并评估疼痛程度。利多卡因/丁卡因7%7%乳膏安全且耐受性好,大多数受试者报告无红斑,浮肿或变白。利多卡因/丁卡因7%7%乳膏未报告相关不良事件;安慰剂乳膏报道了一种与红斑相关的不良事件。这项研究的结果表明,利多卡因/丁卡因7%7%的乳膏能有效减轻透明质酸对软组织的增添疼痛。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号